Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
NCT ID: NCT01129180
Last Updated: 2013-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
8 participants
INTERVENTIONAL
2010-05-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with azacitidine in treating patients with relapsed or refractory T-cell lymphoma.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
II. To define the specific toxicities and the dose-limiting toxicity (DLT) of VELCADE (BORTEZOMIB) in combination with Azacitidine.
SECONDARY OBJECTIVES I. To determine the overall response rate (ORR). II. To correlate the biological activity of Azacitidine as a demethylating agent (changes in target gene methylation and gene expression, DNMT1 protein expression, global methylation) with clinical endpoints and plasma pharmacokinetics of Azacitidine.
III. To characterize the biological activity of VELCADE (BORTEZOMIB) as a potential demethylating agent.
IV. To correlate intracellular concentration of Azacitidine-triphosphate with global DNA methylation and other biological endpoints as well as clinical response.
V. To explore the biologic role of microRNAs in determining clinical response to the VELCADE (BORTEZOMIB) plus Azacitidine combination and achievement of the other pharmacodynamic endpoints.
OUTLINE: This is a dose-escalation study of bortezomib.
Patients receive bortezomib IV on days 4, 8, 11, and 15 and azacitidine subcutaneously (SC) on days 1-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment patients are followed up for at least 30 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I
Patients receive bortezomib IV on days 4, 8, 11, and 15 and azacitidine SC on days 1-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Attempt to collect Correlative studies will be made.
azacitidine
Given SC
bortezomib
Given IV
Correlative studies
Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
azacitidine
Given SC
bortezomib
Given IV
Correlative studies
Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have relapsed or refractory TCL
* Patients must have failed at least one prior systemic therapy
* Life expectancy must be greater than 3 months
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
* Patients must have adequate organ function as defined below:
* Total bilirubin \< 1.5 x upper limit of normal (ULN)
* AST(aspartate aminotransferase) \< 2.0 x ULN
* ALT(Alanine transaminase) \< 2.0 x ULN
* Serum creatinine \< 1.5 ULN
* New York Heart Association Congestive Heart Failure (NYHA CHF) Class II or better
* Platelet count \>= 75,000/mm\^3 (unless due to disease) within 14 days before enrollment
* Absolute neutrophil count of \>= 1,500/mm\^3 within 14 days before enrollment
* Women of childbearing potential must have a negative serum pregnancy test prior to azacitidine treatment; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; if the patient does not agree, the patient is not eligible; women must agree to not get pregnant for the duration of the study; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform the PI or the Study Nurse immediately
* Ability to understand and willingness to sign the written informed consent document before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
* Male subject agrees to use an acceptable method for contraception for the duration of the study
Exclusion Criteria
* Patients receiving any other investigational agents or patients who have received other investigational agents within 14 days of enrollment
* Patients with active central nervous system (CNS) malignancy
* Patients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to Azacitidine or VELCADE (BORTEZOMIB) that are not easily managed; patients with hypersensitivity to VELCADE (BORTEZOMIB), boron, or mannitol
* Patients must not have previously received Azacitidine or VELCADE (BORTEZOMIB) for any disease
* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; as infection is a common feature of TCL, patients with active infection are permitted to enroll provided that the infection is under control; myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities; prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant
* Pregnant women or women who are breastfeeding are excluded from this study; confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening; pregnancy testing is not required for post-menopausal or surgically sterilized women
* HIV-positive patients are ineligible; all patients will be screened for HIV
* Patients with pre-existing Grade 2 or higher neuropathy within 14 days before enrollment or other serious neurologic toxicity that would significantly increase risk of complications from VELCADE (BORTEZOMIB) therapy are excluded
* Patients with active, advanced malignant solid tumors are excluded
* Patients with serious medical or psychiatric illness likely to interfere with participation in this clinical study
* Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Millennium Pharmaceuticals, Inc.
INDUSTRY
Celgene Corporation
INDUSTRY
Pierluigi Porcu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pierluigi Porcu
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierluigi Porcu
Role: PRINCIPAL_INVESTIGATOR
Ohio State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ohio State University Medical Center
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Jamesline
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2010-01081
Identifier Type: REGISTRY
Identifier Source: secondary_id
OSU-08067
Identifier Type: -
Identifier Source: org_study_id